Active Clinical Research for Hepatocellular and Lung Cancer

Comprehensive Cancer Centers runs Phase II and Phase III research trials for the following Hepatocellular and lung cancers:

516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy
Study#: 19018 Phase III
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors **ONLY NSCLC OPEN TO ENROLLMENT**
Study#: i2691 Phase II
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Stage I/II Non-Small Cell Lung Cancer
Study#: i2703 Phase III
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of Atezolizumab Plus Carboplatin And Etoposide With Or Without Tiragolumab (Anti-Tigit Antibody) In Patients With Untreated Extensive Stage Small Cell Lung Cancer **ON HOLD FOR SAFETY RUN IN REVIEW- EXPECTED TO REOPEN IN JUNE 2020**
Study#: 19193 Phase III
Contact Us: For information about this clinical study, Email Us, or use our form field.

Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Study#: 18129 Phase III
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)
Study#: 19208 Phase III
Contact Us: For information about this clinical study, Email Us, or use our form field.

CX-839-014 “KEAPSAKE”: A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Study#: 19239 Phase II
Contact Us: For information about this clinical study, Email Us, or use our form field.